{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:23:14Z","timestamp":1773408194839,"version":"3.50.1"},"reference-count":271,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.critrevonc.2011.05.001","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T22:39:18Z","timestamp":1308263958000},"page":"78-101","source":"Crossref","is-referenced-by-count":59,"title":["Mantle cell lymphoma"],"prefix":"10.1016","volume":"82","author":[{"given":"Sergio","family":"Cortelazzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2011.05.001_bib0005","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"229","article-title":"Mantle cell lymphoma","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0010","first-page":"5432s","article-title":"Non-Hodgkin's lymphoma time trends: United States and international data","volume":"52","author":"Devesa","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejca.2007.12.016","article-title":"Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States","volume":"44","author":"Sant","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0030","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1046\/j.1365-2141.1998.00907.x","article-title":"Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes","volume":"102","author":"Pittaluga","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1365-2141.1997.8712503.x","article-title":"Ongoing immunoglobulin gene mutations in mantle cell lymphomas","volume":"96","author":"Du","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0040","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1182\/blood-2007-08-109611","article-title":"Borrelia infection and risk of non-Hodgkin lymphoma","volume":"111","author":"Schollkopf","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0045","first-page":"300","article-title":"Lymphoid malignancies in Nebraska: a hypothesis","volume":"70","author":"Weisenburger","year":"1985","journal-title":"Nebraska Med J"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00001648-199009000-00004","article-title":"A case-control study of non-Hodgkin's lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska","volume":"1","author":"Zahm","year":"1990","journal-title":"Epidemiology"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0055","first-page":"899","article-title":"Soft tissue sarcoma and non-Hodgkin's lymphoma in relation to phenoxyherbicide and chlorinated phenol exposure in western Washington","volume":"78","author":"Woods","year":"1987","journal-title":"J Natl Cancer Instit"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bjc.1989.290","article-title":"Occupation and lymphoid neoplasms","volume":"60","author":"La Vecchia","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0065","first-page":"5503s","article-title":"Non-Hodgkin's lymphoma and occupational exposure","volume":"52","author":"Scherr","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","article-title":"Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology","volume":"84","author":"Muller","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0075","first-page":"314","article-title":"Familial lymphoid neoplasms in patients with mantle cell lymphoma","volume":"89","author":"Tort","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0080","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1097-0142(19900801)66:3<522::AID-CNCR2820660320>3.0.CO;2-4","article-title":"Mantle zone lymphoma. A clinicopathologic study of 22 cases","volume":"66","author":"Duggan","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0085","first-page":"181","article-title":"Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse","volume":"113","author":"Swerdlow","year":"1983","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0090","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5","article-title":"Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma","volume":"49","author":"Weisenburger","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2559.2007.02906.x","article-title":"In-situ mantle cell lymphoma\u2014a report of two cases","volume":"52","author":"Aqel","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0100","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ajcp\/100.4.373","article-title":"Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features [see comments]","volume":"100","author":"Zukerberg","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/modpathol.3800716","article-title":"Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma","volume":"20","author":"Yin","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0115","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0120","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","article-title":"Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones","volume":"89","author":"Ott","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0130","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0135","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0140","first-page":"18","article-title":"Non-Hodgkin's lymphoproliferative disorders involving the spleen","volume":"10","author":"Arber","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0145","first-page":"712","article-title":"Small lymphocytic lymphomas with predominant splenomegaly: a comparison of immunophenotypes with cases of predominant lymphadenopathy","volume":"4","author":"Hollema","year":"1991","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0150","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0046-8177(03)00286-7","article-title":"Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma","volume":"34","author":"Schenka","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0155","first-page":"260","article-title":"Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems","volume":"13","author":"Chan","year":"1996","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0160","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/ajcp\/105.6.737","article-title":"bc1-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis","volume":"105","author":"Kumar","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0165","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00000478-199604000-00007","article-title":"Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin","volume":"20","author":"Moynihan","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0016-5085(97)70212-9","article-title":"Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D\u2019etude des Lymphomes Digestifs","volume":"112","author":"Ruskone-Fourmestraux","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic variations in mantle cell lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PAI.0b013e3181bb9edf","article-title":"BCL6, MUM1, and CD10 expression in mantle cell lymphoma","volume":"18","author":"Gualco","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0185","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/ajcp\/68.5.535","article-title":"Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas","volume":"68","author":"Nanba","year":"1977","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0190","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2009.008474","article-title":"Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma","volume":"94","author":"Dictor","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0195","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1385\/MO:22:4:327","article-title":"Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis","volume":"22","author":"Walsh","year":"2005","journal-title":"Med Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0205","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","article-title":"VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome","volume":"102","author":"Kienle","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1365-2141.2003.04763.x","article-title":"Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research","volume":"124","author":"Bertoni","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0215","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/path.1781","article-title":"IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome","volume":"206","author":"Cogliatti","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0220","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fernandez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0225","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/modpathol.3800237","article-title":"Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes","volume":"18","author":"Thelander","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0230","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V88.4.1177.bloodjournal8841177","article-title":"Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization","volume":"88","author":"Vaandrager","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0235","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","article-title":"The cellular origin of mantle cell lymphoma","volume":"39","author":"Bertoni","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0240","first-page":"1401","article-title":"Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation","volume":"7","author":"Seto","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2559.1994.tb00533.x","article-title":"The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices","volume":"24","author":"Ott","year":"1994","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0250","first-page":"591","article-title":"bcl-1 rearrangement. Frequency and clinical significance among B-cell chronic lymphocytic leukemias and non-Hodgkin's lymphomas","volume":"138","author":"Athan","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0255","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V76.10.2086.2086","article-title":"Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation","volume":"76","author":"Medeiros","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/path.1711630104","article-title":"Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage","volume":"163","author":"Vandenberghe","year":"1991","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0265","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1073\/pnas.88.21.9638","article-title":"PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma","volume":"88","author":"Rosenberg","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0270","first-page":"5541s","article-title":"Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma","volume":"52","author":"Williams","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0275","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1101\/gad.813200","article-title":"The Rb\/E2F pathway: expanding roles and emerging paradigms","volume":"14","author":"Harbour","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0280","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2002-01-0263","article-title":"Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis","volume":"101","author":"Quintanilla-Martinez","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0285","first-page":"3447","article-title":"Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression","volume":"8","author":"Jiang","year":"1993","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0290","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/j.1460-2075.1994.tb06488.x","article-title":"Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene","volume":"13","author":"Bodrug","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0295","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0300","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1182\/blood-2007-10-118794","article-title":"Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas","volume":"111","author":"Wlodarska","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0305","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0310","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2006-01-0015","article-title":"A chromosomal translocation in cyclin D1-negative\/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus","volume":"108","author":"Gesk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0315","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0320","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0325","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0330","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood.V94.9.3262","article-title":"Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma","volume":"94","author":"Stilgenbauer","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0335","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/blood-2008-02-139212","article-title":"Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma","volume":"112","author":"Gelebart","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0340","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMra020067","article-title":"Molecular diagnosis of the hematologic cancers","volume":"348","author":"Staudt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0345","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus","volume":"65","author":"Hernandez","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0350","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1182\/blood-2006-11-057208","article-title":"Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis","volume":"109","author":"Pinyol","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0355","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0360","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0365","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal","year":"2008","journal-title":"Blood"},{"issue":"(January) 1","key":"10.1016\/j.critrevonc.2011.05.001_bib0370","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"issue":"December (23)","key":"10.1016\/j.critrevonc.2011.05.001_bib0375","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4161\/cc.8.23.10070","article-title":"Targeting mTOR globally in cancer: thinking beyond rapamycin","volume":"8","author":"Shor","year":"2009","journal-title":"Cell Cycle"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2011.05.001_bib0380","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"issue":"September (26)","key":"10.1016\/j.critrevonc.2011.05.001_bib0385","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"July (5)","key":"10.1016\/j.critrevonc.2011.05.001_bib0390","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4161\/auto.6232","article-title":"Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers","volume":"4","author":"Younes","year":"2008","journal-title":"Autophagy"},{"issue":"May (10)","key":"10.1016\/j.critrevonc.2011.05.001_bib0395","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0400","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0405","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0410","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: a population-based clinical study","volume":"14","author":"Velders","year":"1996","journal-title":"J Clin Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2011.05.001_bib0415","article-title":"Mantle-cell lymphoma: classification and therapeutic implications","volume":"7","author":"Fisher","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0420","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.annonc.a058904","article-title":"European Lymphoma Task Force (ELTF): report of the workshop on Mantle Cell Lymphoma (MCL) [see comments]","volume":"5","author":"Zucca","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0425","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvement in mantle cell lymphoma","volume":"19","author":"Ferrer","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0430","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2009.07835.x","article-title":"Mantle cell lymphoma with central nervous system involvement: frequency and clinical features","volume":"147","author":"Gill","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0435","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2141.1998.00684.x","article-title":"Bone marrow and peripheral blood involvement in mantle cell lymphoma","volume":"101","author":"Cohen","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0440","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10428199609067588","article-title":"Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma","volume":"21","author":"Pittaluga","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0445","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jcp.42.9.962","article-title":"Leukaemic phase of mantle zone (intermediate) lymphoma: its characterisation in 11 cases [see comments]","volume":"42","author":"De Oliveira","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0450","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.22715","article-title":"Leukemic involvement is a common feature in mantle cell lymphoma","volume":"109","author":"Ferrer","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0455","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"Bottcher","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0460","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/modpathol.3880144","article-title":"Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma","volume":"13","author":"Viswanatha","year":"2000","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0465","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0470","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.V90.2.894b","article-title":"Serum Ig abnormalities in mantle cell lymphoma [letter; comment]","volume":"90","author":"Preud\u2019homme","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0475","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0480","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00000478-198908000-00008","article-title":"Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type","volume":"13","author":"O\u2019Briain","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0485","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190802216707","article-title":"Positron emission tomography in mantle cell lymphoma","volume":"49","author":"Brepoels","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0490","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0495","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/CLM.2008.n.019","article-title":"[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma","volume":"8","author":"Gill","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0500","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/annonc\/mdn629","article-title":"High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens","volume":"20","author":"Han","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0505","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/10428199909167400","article-title":"Clonality assessment in blood of patients with mantle cell lymphoma [In Process Citation]","volume":"32","author":"Bertoni","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0510","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0515","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0520","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0525","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","article-title":"All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment","volume":"78","author":"Gribben","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0530","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00062752-199502060-00010","article-title":"Molecular methods for monitoring malignant disease after bone marrow transplantation","volume":"2","author":"Lin","year":"1995","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0535","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood.V83.12.3800.3800","article-title":"Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow","volume":"83","author":"Gribben","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0540","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0545","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.3317825","article-title":"Development of the primary antibody repertoire","volume":"238","author":"Alt","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0550","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0301-472X(02)00807-X","article-title":"Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1\/JH rearrangements in mantle cell lymphoma","volume":"30","author":"Andersen","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0555","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0560","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0565","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0570","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0575","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0580","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0585","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/oxfordjournals.annonc.a059154","article-title":"Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period","volume":"6","author":"Norton","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0590","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0595","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0600","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/00000478-199008000-00007","article-title":"Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations","volume":"14","author":"Lardelli","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0605","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0610","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0615","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0620","first-page":"993","article-title":"Retrospective analysis of mantle cell lymphoma: experience of the \u201cGruppo Italiano per lo Studio dei Linfomi\u201d (GISL)","volume":"83","author":"Callea","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0625","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.1996.14.3.941","article-title":"CNS involvement in mantle-cell lymphoma","volume":"14","author":"Montserrat","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0630","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s002770050491","article-title":"Central nervous system involvement in patients with mantle cell lymphoma [In Process Citation]","volume":"78","author":"Oinonen","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0635","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0959-8049(02)00456-2","article-title":"Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma","volume":"39","author":"Raty","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0640","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/10428199709050890","article-title":"Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases","volume":"26","author":"Decaudin","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0645","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0650","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2559.1995.tb00615.x","article-title":"Mantle cell lymphoma: a clinicopathological study of 55 cases","volume":"26","author":"Pittaluga","year":"1995","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0655","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","article-title":"A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors","volume":"38","author":"Andersen","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0660","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0665","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0670","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2006.05970.x","article-title":"Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index","volume":"133","author":"Moller","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0675","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0680","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood-2008-05-155507","article-title":"Mantle cell international prognostic index (MIPI) not prognostic after R-hyper-CVAD","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0685","first-page":"138","article-title":"Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective patient cohort","volume":"114","author":"Hoster","year":"2009","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0690","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0695","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2014a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"25","author":"de Jong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0700","doi-asserted-by":"crossref","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0705","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Bea","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0710","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2141.2002.03260.x","article-title":"Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization","volume":"116","author":"Allen","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0715","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","article-title":"Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome","volume":"105","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0720","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.leukres.2006.10.022","article-title":"Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma","volume":"31","author":"Flordal","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0725","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0730","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)65071-7","article-title":"INK4a\/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene","volume":"156","author":"Pinyol","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0735","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2006.08.7999","article-title":"Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors","volume":"25","author":"Kienle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0740","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2007.12.0410","article-title":"Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue","volume":"26","author":"Hartmann","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0745","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0750","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1365-2141.1997.4693273.x","article-title":"The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group","volume":"99","author":"Vandenberghe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0755","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2006.02.011","article-title":"Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)","volume":"65","author":"Rosenbluth","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0760","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0765","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0770","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/10428190410001723331","article-title":"The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients","volume":"45","author":"Matutes","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0775","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/10428190127511","article-title":"Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma","volume":"42","author":"Yoong","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0780","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0785","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"13","author":"Teodorovic","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0790","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0795","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cncr.20483","article-title":"The role of fludarabine in the treatment of follicular and mantle cell lymphoma","volume":"101","author":"Lenz","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0800","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0805","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0810","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00001622-200403000-00004","article-title":"An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Jacobsen","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0815","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0820","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0825","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0830","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0835","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","article-title":"A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma","volume":"140","author":"Evens","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0840","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0845","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0850","first-page":"769","article-title":"Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the","volume":"112","author":"Dreyling","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0855","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission [see comments]","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0860","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ajcp\/110.5.582","article-title":"Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma","volume":"110","author":"Tworek","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0865","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0870","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0875","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0880","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ncponc0297","article-title":"Is rituximab effective as a single agent in mantle-cell lymphoma?","volume":"2","author":"Grillo-Lopez","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0885","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0890","first-page":"3049","article-title":"The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial","volume":"112","author":"Hoster","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0895","first-page":"12","article-title":"Immunochemotherapy (RMCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone. 50 months up date of the OSHO phase III study (OSHO# 39)","volume":"19","author":"Herold","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0900","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0905","unstructured":"Hoster E, Unterhalt M, Wormann B, et al., on behalf of the German Low-Grade Lymphoma Study Group (GLSG) and the European MCL Network. The addition of Rituximab to First-Line Chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma\u2014long-term results of a GLSG trial. Oncology 2009;32(October (S4)):#V562."},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0910","first-page":"2746","article-title":"Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189)","volume":"108","author":"Inwards","year":"2006","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0915","unstructured":"Dreyling M, Hoster E, Hermine O, et al. European mantle cell lymphoma network: an update on current first line trials. Ann Oncol 2008;19(Suppl. 4):#300."},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0920","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0925","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0930","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0935","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0940","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0945","first-page":"405","volume":"114","author":"Rummel","year":"2009","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0950","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2011.05.001_bib0955","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0960","first-page":"833","article-title":"Rituximab (R)+hypercvad alternating with r-methotrexate\/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL)","volume":"112","author":"Romaguera","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0965","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0970","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1200\/jco.2006.24.18_suppl.7511","article-title":"Mantle cell lymphoma (MCL): induction therapy with hyperCVAD\/high-dose methotrexate and cytarabine (M-C) (\u00b1rituximab) improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose","year":"2006","journal-title":"J Clin Oncol. J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0975","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0980","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bmt.2008.349","article-title":"High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen","volume":"43","author":"Magni","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0985","first-page":"1282","article-title":"Update of a GITIL cohort study: frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma","volume":"110","author":"Cortelazzo","year":"2007","journal-title":"ASH Annual Meet Abstr"},{"issue":"October (7)","key":"10.1016\/j.critrevonc.2011.05.001_bib0990","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Nordic Lymphoma Group.Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib0995","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"van\u2019t Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1000","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","article-title":"Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"104","author":"Thieblemont","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1005","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bbmt.2007.10.019","article-title":"Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma","volume":"14","author":"Dreger","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1015","first-page":"581","article-title":"RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA","volume":"112","author":"Delarue","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1020","doi-asserted-by":"crossref","unstructured":"Hermine O, Hoster E, Walewski J, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network. Blood 2010: abstract #110.","DOI":"10.1182\/blood.V116.21.110.110"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1030","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1035","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/10428190500052461","article-title":"Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature review","volume":"46","author":"Grigg","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1040","first-page":"3051","article-title":"autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: extended follow-up of a matched pair analysis","volume":"108","author":"Hicks","year":"2006","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1045","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1050","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/jco.2006.24.18_suppl.7533","article-title":"Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL network and the PLRG","volume":"24","author":"Weigert","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1055","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/jco.2006.24.18_suppl.7503","article-title":"Phase II study of rituximab+CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1499)","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1060","first-page":"2747","article-title":"90Y-Zevalin(R) (90Y-Ibritumomab Tiuxetan) radioimmunotherapy (RIT) consolidation of FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: results from the PLRG upon completed enrollment","volume":"108","author":"Jurczak","year":"2006","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1065","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1200\/jco.2006.24.18_suppl.7560","article-title":"Sequential radioimmunotherapy with tositumomab\/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Zelenetz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1075","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1085","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1090","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1095","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1700989","article-title":"Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation","volume":"20","author":"Tsai","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/sj.bmt.1701918","article-title":"Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"24","author":"Ringden","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1115","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bmt.1701033","article-title":"Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy","volume":"21","author":"Kroger","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1125","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s002770000196","article-title":"Allogeneic bone marrow transplantation for refractory mantle cell lymphoma","volume":"79","author":"Kroger","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1130","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1135","first-page":"3123","article-title":"Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma. A retrospective analysis from the EBMT Lymphoma Working Party","volume":"108","author":"Avivi","year":"2006","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1140","first-page":"457","article-title":"Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma. An Analysis from the Lymphoma Working Party of the EBMT","volume":"112","author":"Robinson","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1145","first-page":"2147","article-title":"Sustained graft-versus-lymphoma effect among patients (pts) with mantle cell lymphoma (MCL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)","volume":"112","author":"Sorror","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1150","first-page":"1965","article-title":"Interest of non-myeloablative allogeneic stem cell transplantation in mantle cell lymphoma: a multicenter retrospective study","volume":"112","author":"Le Gouill","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1155","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1160","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10428190400029841","article-title":"Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP","volume":"46","author":"Thomas","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1170","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1175","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1200\/jco.2004.22.14_suppl.6697","article-title":"Results of a pilot trial of fludarabine, mitoxantrone and rituximab in mantle cell lymphoma","volume":"22","author":"Mohrbacher","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1180","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study","volume":"15","author":"Jermann","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1185","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","article-title":"Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma","volume":"18","author":"Morschhauser","year":"2007","journal-title":"Ann Oncol"},{"issue":"July (5)","key":"10.1016\/j.critrevonc.2011.05.001_bib1190","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-4598-7-40","article-title":"Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma","volume":"May (7)","author":"Yang","year":"2008","journal-title":"Mol Cancer"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2011.05.001_bib1200","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/10428190801910912","article-title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways","volume":"49","author":"Rizzatti","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2011.05.001_bib1205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"P\u00e9rez-Gal\u00e1n","year":"2006","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2011.05.001_bib1210","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.727.727","article-title":"NRF2 at the interface of oxidative and endoplasmic reticulum stress pathways is a critical integrator of bortezomib response in mantle cell lymphoma in vitro and in vivo","volume":"114","author":"Weniger","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2011.05.001_bib1215","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1073\/pnas.0807611106","article-title":"ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells","volume":"106","author":"Wang","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1220","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1225","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1230","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1235","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1240","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1245","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1250","first-page":"3051","article-title":"Phase I trial of bortezomib in combination with rituximab-HYPERCVAD\/methotrexate and cytarabine for untreated mantle cell lymphoma","volume":"112","author":"Romaguera","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1255","first-page":"265","article-title":"VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin oncology network","volume":"112","author":"Kahl","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1260","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma\u2014long-term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2011.05.001_bib1265","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"issue":"November (5)","key":"10.1016\/j.critrevonc.2011.05.001_bib1270","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"issue":"November (22)","key":"10.1016\/j.critrevonc.2011.05.001_bib1275","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O\u2019Connor","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"March (5)","key":"10.1016\/j.critrevonc.2011.05.001_bib1280","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1285","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1290","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1295","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1182\/blood.V108.11.2714.2714","article-title":"Phase II study of Yttrium 90 (90Y) Ibritumomab Tiuxetan Zevalin\u00ae) in patients with relapsed and refractory Mantle Cell Lymphoma (MCL)","volume":"108","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1300","article-title":"International study of lenalidomide in relapsed\/refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Cruczman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1305","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1310","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1315","first-page":"262","article-title":"Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of An International Study (NHL-003)","volume":"112","author":"Zinzani","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1320","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1325","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1330","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1335","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1340","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1345","first-page":"899a","article-title":"Early and robust immune responses to idiotype (Id) vaccination occur in mantle cell lymphoma (MCL) and indolent lymphoma (IL) patients following autologous stem cell transplantation (ASCT)","volume":"102","author":"Holman","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1350","article-title":"Recombinant idiotype-KLH vaccination (MyVaxTM) following CHOP chemotherapy in mantle cell lymphoma","author":"Leonard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.05.001_bib1355","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811001338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811001338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T05:48:23Z","timestamp":1592632103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842811001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":271,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1040842811001338"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2011.05.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}